Literature DB >> 8020168

Prevention by acetylsalicylic acid of liver cirrhosis and carcinogenesis as well as generations of 8-hydroxydeoxyguanosine and thiobarbituric acid-reactive substances caused by a choline-deficient, L-amino acid-defined diet in rats.

A Denda1, Q Tang, T Endoh, T Tsujiuchi, K Horiguchi, O Noguchi, Y Mizumoto, D Nakae, Y Konishi.   

Abstract

Effects of acetylsalicylic acid (ASA) (aspirin) on the pathogenesis of fatty liver, cirrhosis and hepatocarcinogenesis caused by a choline-deficient L-amino acid-defined (CDAA) diet were examined in male Fischer 344 rats fed a CDAA diet supplemented with 0, 0.1, 0.2, 0.4 or 0.8% ASA for 30 weeks. ASA at concentrations of > 0.2% prevented the development of both cirrhosis and preneoplastic and neoplastic nodules, but without any directly associated prevention of fatty changes. ASA also prevented hepatocyte proliferation and the generation of thiobarbituric acid-reactive substances and 8-hydroxydeoxyguanosine caused by feeding the CDAA diet, analyzed, respectively, after 1, 12 and 12 weeks. The results clearly indicate that the anti-inflammatory drug ASA, which is not a lipotropic factor, can prevent the pathogenesis of cirrhosis and hepatocarcinogenesis caused by a CDAA diet, which is possibly partly associated with the prevention of reactive oxygen species production.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8020168     DOI: 10.1093/carcin/15.6.1279

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  7 in total

Review 1.  Prevention of hepatocellular carcinoma: potential targets, experimental models, and clinical challenges.

Authors:  Yujin Hoshida; Bryan C Fuchs; Kenneth K Tanabe
Journal:  Curr Cancer Drug Targets       Date:  2012-11-01       Impact factor: 3.428

Review 2.  Cyclooxygenases in hepatocellular carcinoma.

Authors:  Melchiorre Cervello; Giuseppe Montalto
Journal:  World J Gastroenterol       Date:  2006-08-28       Impact factor: 5.742

3.  The beneficial effect of aspirin and enoxaparin on fibrosis progression and regenerative activity in a rat model of cirrhosis.

Authors:  Nimer Assy; Osamah Hussein; Abdallah Khalil; Anthony Luder; Sergio Szvalb; Melia Paizi; Gadi Spira
Journal:  Dig Dis Sci       Date:  2007-05       Impact factor: 3.487

4.  Inhibition by green tea extract of diethylnitrosamine-initiated but not choline-deficient, L-amino acid-defined diet-associated development of putative preneoplastic, glutathione S-transferase placental form-positive lesions in rat liver.

Authors:  K Tamura; D Nakae; K Horiguchi; H Akai; Y Kobayashi; H Satoh; T Tsujiuchi; A Denda; Y Konishi
Journal:  Jpn J Cancer Res       Date:  1997-04

5.  Effects of aspirin and enoxaparin in a rat model of liver fibrosis.

Authors:  Chen-Jie Li; Zhi-Hui Yang; Xiao-Liu Shi; De-Liang Liu
Journal:  World J Gastroenterol       Date:  2017-09-21       Impact factor: 5.742

6.  Aspirin targets P4HA2 through inhibiting NF-κB and LMCD1-AS1/let-7g to inhibit tumour growth and collagen deposition in hepatocellular carcinoma.

Authors:  Tianjiao Wang; Xueli Fu; Tianzhi Jin; Lu Zhang; Bowen Liu; Yue Wu; Feifei Xu; Xue Wang; Kai Ye; Weiying Zhang; Lihong Ye
Journal:  EBioMedicine       Date:  2019-07-02       Impact factor: 8.143

7.  Inhibition of early-phase exogenous and endogenous liver carcinogenesis in transgenic rats harboring a rat glutathione S-transferase placental form gene.

Authors:  D Nakae; A Denda; Y Kobayashi; H Akai; H Kishida; T Tsujiuchi; Y Konishi; T Suzuki; M Muramatsu
Journal:  Jpn J Cancer Res       Date:  1998-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.